Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sepiapterin · Sephience, PTC-923

Small molecule · Activator of phenylalanine hydroxylase (PAH) · developed by Ptc Therap

Approved FDA, Jul 2025
PTCT Developer
3 Registered trials

What is Sepiapterin?

Sepiapterin is a precursor of the enzymatic cofactor tetrahydrobiopterin (BH4), which activates phenylalanine hydroxylase (PAH). It is used to treat hyperphenylalaninemia in sepiapterin-responsive phenylketonuria, given alongside a phenylalanine-restricted diet.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Sephience, PTC-923, CNSA-001
Drug type
Small molecule
Targets
phenylalanine hydroxylase (PAH)
Mechanism
Activator of phenylalanine hydroxylase (PAH)
Pathways
tetrahydrobiopterin (BH4) cofactor synthesis
Therapy area
Gastroenterology, Neurology
Developer
Ptc Therap (PTCT)
FDA status
Approved as Sephience (July 28, 2025), NDA219666 · FDA label
UNII
CJQ26KO7HP

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 24, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06302348 Phase 3 Phenylketonuria Recruiting PTCT
NCT05166161 Phase 3 Phenylketonuria Completed PTCT
NCT03712124 Phase 2 Gastroparesis Completed PTCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

GastroparesisPhenylketonuria

Other drugs acting on PAH

More from Ptc Therap

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PTCT page.

Follow PTCT, the company behind Sepiapterin

See PTCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PTCT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.